News

Proteologics has anti-viral drug discovery programs based on proprietary research of host-protein ubiquitin-ligase drug targets shown to be essential for the HIV life cycle. Proteologics strategy is to

The acquisition is expected to add more than $55 million in sales annually and be accretive to earnings in the first year. Joseph Papa, chairman and CEO of

The company said that this is the first issuance from a series of patent applications covering its XmAb antibody Fc engineering technology, which is comprised of a suite

In exchange for a full release of claims, Dey has agreed to pay the state $4.75 million, of which $750,000 accounts for outside legal fees and expenses. As

The company will be selling 8.7 million shares of its common stock at a price of $3 per share, which represents a 40% premium above the closing sale

The preclinical study evaluated the extent of absorption of lorazepam after nasal administration and the pharmacokinetics of the novel formulation. Amarin is working with a subsidiary of Elan

This study will evaluate the safety and pharmacokinetics of R348 in young, healthy males using a double-blind, placebo-controlled, single dose and multiple rising doses of R348. Results are

The nCounter analysis system at Washington University will be utilized first for a large-scale diabetes study to validate the expression of over 50 genes across 15 tissues in

The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary antitumor activity of TRC105 in patients with advanced cancer. Charles Theuer,